看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 5.1x - 5.6x | 5.3x |
| Selected Fwd EBITDA Multiple | 5.5x - 6.0x | 5.8x |
| Fair Value | $12.38 - $13.70 | $13.04 |
| Upside | 31.9% - 46.1% | 39.0% |
| Benchmarks | Ticker | Full Ticker |
| Aquestive Therapeutics, Inc. | AQST | NasdaqGM:AQST |
| Amneal Pharmaceuticals, Inc. | AMRX | NasdaqGS:AMRX |
| Teva Pharmaceutical Industries Limited | 0LER | LSE:0LER |
| Titan Pharmaceuticals, Inc. | TTNP | NasdaqCM:TTNP |
| Pfizer Inc. | 0Q1N | LSE:0Q1N |
| Indivior PLC | INDV | NasdaqGS:INDV |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| AQST | AMRX | 0LER | TTNP | 0Q1N | INDV | ||
| NasdaqGM:AQST | NasdaqGS:AMRX | LSE:0LER | NasdaqCM:TTNP | LSE:0Q1N | NasdaqGS:INDV | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | 20.4% | 0.0% | NM- | 11.0% | 8.1% | |
| 3Y CAGR | NM- | 9.1% | 0.2% | NM- | -10.1% | 16.7% | |
| Latest Twelve Months | -118.7% | 16.7% | 2.3% | 36.5% | 24.2% | 14.1% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -63.2% | 20.0% | 27.1% | -14556.3% | 34.6% | 21.3% | |
| Prior Fiscal Year | -27.1% | 20.9% | 27.3% | -3894.0% | 31.5% | 25.3% | |
| Latest Fiscal Year | -52.2% | 20.9% | 26.8% | NA | 36.7% | 26.6% | |
| Latest Twelve Months | -52.2% | 20.9% | 26.8% | NA | 36.7% | 26.6% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 4.31x | 1.82x | 1.98x | NA | 2.90x | 1.01x | |
| EV / LTM EBITDA | -8.3x | 8.7x | 7.4x | -0.2x | 7.9x | 3.8x | |
| EV / LTM EBIT | -8.1x | 14.6x | 9.7x | -0.2x | 11.3x | 4.1x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -8.3x | 7.4x | 8.7x | ||||
| Historical EV / LTM EBITDA | 3.8x | 8.0x | 17.0x | ||||
| Selected EV / LTM EBITDA | 5.1x | 5.3x | 5.6x | ||||
| (x) LTM EBITDA | 316 | 316 | 316 | ||||
| (=) Implied Enterprise Value | 1,599 | 1,684 | 1,768 | ||||
| (-) Non-shareholder Claims * | (27) | (27) | (27) | ||||
| (=) Equity Value | 1,572 | 1,657 | 1,741 | ||||
| (/) Shares Outstanding | 124.8 | 124.8 | 124.8 | ||||
| Implied Value Range | 12.60 | 13.28 | 13.95 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 12.60 | 13.28 | 13.95 | 9.38 | |||
| Upside / (Downside) | 34.4% | 41.6% | 48.8% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AQST | AMRX | 0LER | TTNP | 0Q1N | INDV | |
| Enterprise Value | 249 | 5,061 | 32,734 | 1 | 186,631 | 1,197 | |
| (+) Cash & Short Term Investments | 72 | 112 | 3,300 | 3 | 20,477 | 320 | |
| (+) Investments & Other | 0 | 36 | 0 | 0 | 2,107 | 27 | |
| (-) Debt | (38) | (2,593) | (18,184) | 0 | (67,418) | (374) | |
| (-) Other Liabilities | 0 | (65) | (347) | 0 | (294) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | (0) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 283 | 2,551 | 17,503 | 4 | 141,503 | 1,170 | |
| (/) Shares Outstanding | 98.9 | 310.0 | 1,145.8 | 0.9 | 5,671.5 | 124.8 | |
| Implied Stock Price | 2.86 | 8.23 | 15.28 | 3.94 | 24.95 | 9.38 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2.86 | 8.23 | 15.28 | 3.94 | 24.95 | 9.38 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |